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Abstract
Background—Most surgeons believe that graft choice for ACL reconstruction is an important 
factor related to outcome. Although graft choice may be limited in the revision setting based on 
previously used grafts, it is still felt to be important.
Hypothesis—The purpose of this study was to determine if revision ACL graft choice predicts 
outcomes related to sports function, activity level, OA symptoms, graft re-rupture, and reoperation 
at two years following revision reconstruction. We hypothesized that autograft use would result in 
increased sports function, increased activity level, and decreased OA symptoms (as measured by 
validated patient reported outcome instruments). Additionally, we hypothesized that autograft use 
would result in decreased graft failure and reoperation rate 2 years following revision ACL 
reconstruction.
Study Design—Prospective cohort study; Level of evidence, 2.
Methods—Revision ACL reconstruction patients were identified and prospectively enrolled by 
83 surgeons over 52 sites. Data collected included baseline demographics, surgical technique and 
pathology, and a series of validated patient reported outcome instruments (IKDC, KOOS, 
WOMAC, and Marx activity rating score). Patients were followed up at 2 years, and asked to 
complete the identical set of outcome instruments. Incidence of additional surgery and reoperation 
due to graft failure were also recorded. Multivariate regression models were used to determine the 
predictors (risk factors) of IKDC, KOOS, WOMAC, Marx scores, graft re-rupture, and 
reoperation rate at 2 years following revision surgery.
Results—1205 patients were successfully enrolled with 697 (58%) males. Median age was 26. In 
88% this was their first revision. 341 (28%) were undergoing revision by the surgeon that had 
performed the previous reconstruction. 583 (48%) underwent revision reconstruction utilizing an 
autograft, 590 (49%) allograft, and 32 (3%) both autograft and allograft. Median time since their 
last ACL reconstruction was 3.4 years. Questionnaire follow-up was obtained on 989 subjects 
(82%), while phone follow-up was obtained on 1112 subjects (92%). The IKDC, KOOS, and 
WOMAC scores (with the exception of the WOMAC stiffness subscale) all significantly improved 
at the two year follow-up time point (p<0.001). In contrast, the two year MARX activity scale 
demonstrated a significant decrease from the initial score at enrollment (p<0.001).
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Graft choice proved to be a significant predictor of 2 year IKDC scores (p=0.017). Specifically, 
the use of an autograft for revision reconstruction predicted improved score on the IKDC 
[p=0.045; Odds Ratio (OR) = 1.31; 95% confidence intervals (CI) = 1.01, 1.70]. The use of an 
autograft predicted an improved on the KOOS subscale Sports and Recreation (p=0.037; 
OR=1.33; 95% CI=1.02, 1.73). Use of an autograft also predicted improved scores on the KOOS 
subscale Quality of Life (QOL) (p=0.031; OR=1.33; 95% CI=1.03, 1.73). For the KOOS 
Symptoms and ADL subscales, graft choice did not predict outcome score. Graft choice also 
proved to be a significant predictor of 2 year Marx activity level scores (p=0.012).
Graft re-rupture was reported in 37/1112 (3.3%) of patients by their two year follow-up: 24 
allografts, 12 autografts, and 1 allograft + autograft. Use of an autograft for revision resulted in 
patients 2.78 times less likely to sustain a subsequent graft rupture than if an allograft was utilized 
(p=0.047; 95% CI=1.01, 7.69).
Conclusions—Improved sports function and patient reported outcome measures are obtained 
when an autograft is utilized. Additionally, use of an autograft shows a decreased risk in graft re-
rupture at two years follow-up. No differences were noted in rerupture or patient reported 
outcomes between soft tissue and bone-patellar tendon-bone grafts. Surgeon education regarding 
the findings in this study can result in potentially improved revision ACL reconstruction results 
for our patients.
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Introduction
Revision anterior cruciate ligament (ACL) reconstruction remains challenging for patients 
and surgeons. Multiple studies have demonstrated worse clinical outcomes for revision 
reconstructions as compared to primary reconstructions.5,13,25,26 These outcomes combined 
with confirmatory beliefs by orthopedic sports medicine surgeons resulted in the 
development of the MARS group. The goal was to establish a prospective longitudinal 
cohort to evaluate the predictors of outcome in ACL revision reconstruction.
Most surgeons believe that graft choice for ACL reconstruction is an important factor related 
to outcome. Less outcome evidence exists in the revision setting compared to primary ACL 
reconstruction, but most surgeons believe it remains important. Graft choice may be limited 
in the revision setting based on previously used grafts. Thus, surgeons are interested in the 
impact of both allograft versus autograft and soft tissue versus patellar tendon choices to 
determine how important it is to pursue different grafts in the revision setting. Previous 
prospective cohorts have demonstrated an increased failure rate of allografts in young, high 
activity patients.12 As such, one of the goals of our prospective MARS cohort was to 
determine if this remained true in the revision setting or if more modern allograft processing 
and other factors in the revision setting would result in a similar allograft/autograft failure 
rate.
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The purpose of this study was to determine if graft choice predicts outcomes related to 
sports function, activity level, osteoarthritis (OA) symptoms, graft re-rupture, and 
reoperation at two years following revision ACL reconstruction. We hypothesized that 
autograft use would result in increased sports function, increased activity level, and 
decreased OA symptoms (as measured by validated patient reported outcome instruments). 
Additionally, we hypothesized that autograft use would result in decreased graft failure and 
reoperation rate2 years following revision ACL reconstruction.
Methods
Setting and Study Population
The MARS group is comprised of 83 surgeons over 52 sites. Surgeons were a 50/50 mix of 
academic and private practitioners that were all sports medicine fellowship trained. 
Enrollment began in 2006 and ended June 30, 2011, in which 1205 revision ACL 
reconstruction patients were enrolled in this prospective longitudinal cohort.(Figure 1) 
Inclusion criteria incorporated any patients undergoing revision of a previously failed ACL 
reconstruction who agreed to participate and filled out an informed consent and a series of 
patient reported outcome instruments. Multi-ligament reconstructions were excluded. 
Surgeon inclusion criteria was comprised of completion of a training session that integrated 
articular cartilage and meniscus agreement studies, review of study design and patient 
inclusion criteria and a review of the surgeon questionnaire. Surgeons performed the surgery 
as they desired with the only stipulation that if an allograft was used it must be supplied by 
the Musculoskeletal Transplant Foundation (MTF; Edison, NJ). This was a stipulation to 
control and make consistent allograft source and processing given the importance of the 
allograft versus autograft question. Processing of the allografts was as follows: MTF used a 
technique for evaluating the incoming tissue called The Vanguard Method™. MTF took 
actual samples of bone and soft tissue from every area that was to be used for transplantable 
grafts and destructively tested them which told potential organism and bioburden. From 
these results the tissue had 4 potential pathways: 1) solely processed aseptically; 2) 
depending on the type of organism and level, the tissue was discarded entirely; 3) the whole 
donor was sent for a bulk tissue gamma radiation treatment of 1.2-1.8 mRAD as a pre-
treatment step prior to processing; or 4) in a small number of cases due to surgeon request 
terminal irradiation of 0.7-1.0 mRAD was delivered. Of the patients that received allografts 
247 (42%) were processed aseptically, 313 (53%) received low dose whole body irradiation 
and 31 (5%) received 0.7-1.0 mRAD terminal irradiation.
Data Sources and Measurement
After informed consent was obtained, each participant completed a 13-page questionnaire 
that encompassed baseline demographics, injury descriptors, sports participation level, 
comorbidities, knee surgical history, and patient reported outcome measures that included 
the International Knee Documentation Committee (IKDC),10 Knee injury and Osteoarthritis 
Outcome Score (KOOS) five subscales (symptoms, pain, activities of daily living [ADL], 
sports and recreation, knee-related quality of life),18-20, the Western Ontario and McMaster 
Universities Osteoarthritis Index (WOMAC),1,2,8 and the Marx activity rating scale.15 Their 
validity, reliability, responsiveness to clinical change, and minimal clinically meaningful 
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differences have been previously documented.23,24 All questionnaires were completed prior 
to the procedure.
Immediately following the surgical procedure, each surgeon completed a 49-page 
questionnaire that documented the results of the exam under anesthesia, surgical technique, 
and the arthroscopic findings and treatment of concomitant meniscal and cartilage injury.7 
Surgeon documentation of articular cartilage injury was recorded based on the modified 
Outerbridge classification.16 Meniscus injuries were classified by size, location, and partial 
versus complete tears, while treatment was recorded as not treated, repair, or extent of 
resection.
Completed data forms were mailed from each participating site to the data coordinating 
center. Data from both the patient and surgeon questionnaires were scanned with 
Teleform™ software (Cardiff Software, Inc., Vista, CA) utilizing optical character 
recognition, and the scanned data was verified and exported to a master database. A series of 
logical error and quality control checks were subsequently performed prior to data analysis.
Patient Follow-up
Two year follow-up was completed by mail with re-administration of the same questionnaire 
to each patient, which included the same outcome measures (IKDC, KOOS, WOMAC, 
MARX activity scale) as completed at baseline. Patients were also contacted by telephone to 
determine if graft failure and any subsequent surgeries had occurred since their initial 
revision reconstruction.
Quantitative Variables and Statistical Methods
Multivariable regression models were utilized to examine the independent (risk factor) 
variables and incidence of graft failure, reoperation rate, and sports function at two years 
following ACL revision surgery. For the ordinal outcome measures, analysis was performed 
using a proportional odds logistic regression model. Binary outcome measures analysis was 
performed using a logistic regression model. Parameter estimates were exponentiated to 
obtain odds ratios along with their corresponding 95% confidence intervals. The dependent 
variables were treated as either categorical or continuous and consisted of graft failure (yes/
no), reoperation (yes/no), IKDC (scored 0 [worst] to 100 [best]), KOOS (scored 0 [worst] to 
100 [best]), WOMAC (scored 0 [worst] to 100 [best]), and the Marx (scored 0 [low activity] 
to 16 [highest activity]). Independent patient-related covariates controlled for in the model 
included age at the time of surgery, gender, body mass index (BMI), smoking status, 
education level, activity level as assessed using the Marx activity rating scale, and baseline 
measure of the outcome (IKDC, KOOS, WOMAC, and Marx) (Table 1). All continuous 
covariates were modeled using a 3 knot restricted cubic spline to allow for a nonlinear 
relationship with the outcomes measures.
Independent surgical-related covariates controlled for in the model encompassed previous 
surgical characteristics and findings, as well as surgical characteristics and findings at the 
time of revision (Table 1). Previous surgical characteristics included the revision number, 
previous ACL reconstruction on the contralateral knee (yes/no), previous meniscal 
pathology, surgeon's opinion of cause of failure, and prior graft type. Time from previous 
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ACL reconstruction (calculated as the time from the patient's previous ACL surgery to the 
date that the patient had their revision ACL surgery) was included in the model, and treated 
as a continuous variable. Current surgical characteristics included individual surgeon, 
mechanism of injury, current revision graft type (autograft, allograft, both), graft source 
(BTB, soft tissue, other), surgical technique, meniscal and articular cartilage pathology and 
treatment.
Regarding minimal clinically important difference (MCID) change in score, we utilized 11 
points for the IKDC,11 8-10 points for the KOOS' five subscales,17 8-10 points for the 
WOMAC23,24 and 2 points for the Marx activity scale. To avoid casewise deletion of 
records with missing covariates we employed multiple imputation via prediction mean 
matching. Statistical analysis was performed with the free open source R statistical software 
using the Hmisc and rms package (http://www.r-project.org).9
Results
Study Population
Table 2 provides a synopsis of the baseline patient and surgical characteristics of our cohort. 
1205 patients enrolled with 697 (58%) males. Median age was 26. In 88% this was their first 
revision. 341 (28%) were undergoing revision by the surgeon that had performed the 
previous reconstruction. 50% of the surgeons were in private practice while 50% were 
involved in an academic practice. 583 (48%) underwent revision reconstruction utilizing an 
autograft, 590 (49%) allograft, and 32 (3%) both autograft and allograft. Median time since 
their last ACL reconstruction was 3.4 years. A two stage procedure for bone grafting of 
tunnels was performed 7% of the time for the femur and 8% for the tibia.
Two Year Follow-up
Questionnaire follow-up was obtained on 989 subjects (82%), while phone follow-up was 
obtained on 1112 subjects (92%). There were 6 subjects who underwent a total knee 
arthroplasty by the 2 year follow-up, and as such, no follow-up questionnaire was required 
to be completed from these subjects.
Patient Reported Outcomes (IKDC, KOOS, WOMAC, and Marx Activity Level)
Table 3 summarizes and compares the median patient reported outcome scores between 
baseline and 2 years. The IKDC, KOOS, and WOMAC scores (with the exception of the 
WOMAC stiffness subscale) all significantly improved at the two year follow-up time point 
(p<0.001). These improvements all surpassed their respective MCIDs, illustrating that 
revision ACL surgery was beneficial to this cohort. However, the two year KOOS knee-
related quality of life subscale, although showing significant improvement at the 2 year 
mark (31 vs. 56), falls well below the previously reported primary ACL score of 75 at the 
same 2 year follow-up time.21
In contrast to the IKDC, KOOS, and WOMAC scores, the two year MARX activity scale 
demonstrated a significant decrease from the initial score at enrollment (p<0.001). At 
baseline the median score was an 11 (out of a 16 point scale) with the 75th percentile score a 
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16. At 2 years the median dropped to 7 and the 75th dropped to 12. To illustrate this point, 
we calculated the number of patients who scored either a “0” (lowest) or “16” (highest Marx 
value) at baseline, and compared it to the number of patients who rated themselves either 
“0” or “16” at two years. Only patients in which we had both baseline and 2 year Marx 
scores were included (n=980). There were 124 patients who rated themselves a “0” at 
baseline (or 12.7% of our cohort), increasing to 165 patients at two years (16.8% of our 
cohort; a 4% increase). Similarly, there were 281 patients who rated themselves a “16” at 
baseline (28.7% of our cohort), which decreased to 109 subjects at two years (11.1% of our 
cohort; a nearly 18% decrease). This reflects a substantial number of subjects who ratcheted 
down their frequency of playing high level sports (172 subjects), or essentially dropped their 
activity to sedentary levels (41 subjects).
Influence of Graft Choice on Two Year Patient Reported Outcomes
IKDC—Graft choice proved to be a significant predictor of 2 year IKDC scores (p=0.017). 
Specifically, the use of an autograft for revision reconstruction predicted improved score on 
the IKDC[p=0.045; Odds Ratio (OR) = 1.31; 95% confidence intervals (CI) = 1.01, 1.70]. 
Subjects who had a combination autograft plus allograft (at the time of revision surgery, 32 
patients) also had improved IKDC outcomes at 2 years (p=0.022; OR=2.77; 95% CI=1.16, 
6.64). Additional factors that predicted an improved IKDC score included a higher baseline 
IKDC score (p<0.001; OR=3.06; 95% CI=2.50, 3.74), male gender (p<0.001; OR=1.64; 
95% CI=1.25, 2.13), a longer time since the last ACL reconstruction (p=0.010; OR=1.92; 
95% CI=1.30, 2.82) and a higher baseline Marx activity score (p=0.023; OR=2.21; 95% 
CI=1.55, 3.15).
KOOS—Knee sports and recreation score on the KOOS demonstrated higher scores in the 
setting of an autograft compared to allograft for revision reconstruction (p=0.037; OR=1.33; 
95% CI=1.02, 1.73). Other factors which predicted improved score were similar to the 
IKDC, including a higher baseline KOOS sports/rec score (p<0.001; OR=2.97; 95% 
CI=2.42, 3.63), higher baseline Marx score (p=0.001; OR=1.81; 95% CI=1.26, 2.59), and a 
longer time since previous reconstruction (p=0.008; OR=2.03; 95% CI=1.38, 2.99). For 
KOOS subscale quality of life (QOL) autograft also predicted improved scores (p=0.031; 
OR=1.33; 95% CI=1.03, 1.73). For the KOOS symptoms and ADL subscales, graft choice 
did not predict outcome score.
WOMAC—The stiffness subscale on the WOMAC demonstrated higher scores in subjects 
who had a graft consisting of the combination of bone-tendon-bone (BTB) with a soft tissue 
graft (n=14; p=0.029; OR=6.48; 95% CI=1.22, 34.57). Additional factors which predicted 
less knee stiffness via the WOMAC were better baseline WOMAC stiffness scores 
(p<0.001; OR=4.34; 95% CI=3.39, 5.56) and a longer time since previous reconstruction 
(p=0.003; OR=1.77; 95% CI=1.19, 2.63).
MARX—Graft choice also proved to be a significant predictor of 2 year Marx activity level 
scores (p=0.012). Specifically, the use of a combination autograft plus allograft for revision 
reconstruction predicted improved scores on the Marx (p=0.005; OR= 3.33; 95% CI=1.43, 
7.78). Additional factors which predicted an improved 2 year Marx activity level score 
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included a higher baseline Marx score (p<0.001; OR=5.79; 95% CI=4.01, 8.35), male 
gender (p<0.001; OR=1.79; 95% CI=1.39, 2.33), younger age (p<0.001; OR=2.17; 95% 
CI=1.41, 3.23), and if it was the surgeon's own failure (p=0.017; OR=1.54; 95% CI=1.08, 
2.19). Factors which predicted a lower activity level at 2 years included subjects who were 
current smokers at the time of revision surgery (p=0.018; OR=1.72; 95% CI=1.10, 2.70), 
subjects having a previous ACL reconstruction on the contralateral leg (p=0.047; OR=1.49; 
95% CI=1.01, 2.22), and those incurring a biologic enhancement at the time of revision 
surgery (p=0.019; OR=1.82; 95% CI=1.11, 3.03).
Influence of Graft Choice on Predicting Graft Re-rupture and Reoperations at Two Years 
Graft Re-rupture
Graft re-rupture was reported in 37/1112 (3.3%) of patients by their two year follow-up: 
24/540 (4.4%) allografts, 12/542 (2.2%) autografts, and 1/29 (3.4%) allograft + autograft. 
Subjects with an autograft revision were found to have a 2.78 times less likely risk of 
sustaining a subsequent graft rupture than if an allograft was utilized (p=0.047; 95% 
CI=1.01, 7.69). The 25 patients that had rerupture with an allograft included 13 (52%)treated 
aseptically, 11 (44%) treated with whole body irradiation and 1 (3%) treated with terminal 
irradiation. The use of BTB versus soft tissue grafts did not impact graft re-rupture rate for 
either allograft or autograft usage. Analysis of additional predictors for graft re-rupture 
demonstrated that the number of previous revisions significantly predicted risk for future 
graft rupture. Specifically, patients undergoing revision number 3 or higher were 25.8 times 
more likely to sustain a subsequent graft re-rupture by 2 years following their enrollment 
surgery (p=0.021; CI=1.65, 400).
Reoperation
One hundred fifty (150/1112, or 13.5%) patients underwent reoperation in the 2 years since 
their revision reconstruction. For this specific analysis, we eliminated reoperations that 
included meniscal transplant (n=4), high tibial osteotomy (n=6) and knee replacement (n=6) 
because we believe that these were not related to graft choice. The included reoperations in 
the analysis were chondroplasty and other articular cartilage treatment procedures, 
meniscectomy, meniscal repair and hardware removal. Analysis demonstrated that graft 
choice was not a predictor of incidence of subsequent reoperations at two years following 
revision surgery. However, patients undergoing their 3rd revision or higher were 4.7 times 
more likely to incur subsequent surgeries (p=0.016; CI=1.34, 16.4).
Discussion
This study demonstrates the successful ability of the MARS group to prospectively collect 
and analyze a large revision ACL reconstruction cohort and has many strengths. To our 
knowledge, this is the largest revision ACL reconstruction patient cohort ever studied. 
Previously, in the 21 studies with minimum 2 year follow-up analyzed by systematic review 
there was a collective total of 863 patients in the entire 21 studies.26 This current cohort with 
follow-up on greater than 1000 patients eclipses the collective previous patients documented 
in the medical literature. The large cohort (n=1205) allows for inclusion of a large number 
of variables (88) to be controlled for in the modeling, while keeping within statistical rules 
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requiring 10 subjects per variable for multivariate analysis. Based on the 50/50 mix of the 
academic and private practice surgeons our results are generalizable to the sports medicine 
community. Our findings support our hypothesis that graft choice was a predictor for 2 year 
revision ACL reconstruction outcomes. Specifically, the use of autograft resulted in 
improved sports function and activity level as measured by patient reported outcome 
measures. Also consistent with our hypothesis was that the use of autograft decreased the 
likelihood of subsequent graft rupture.
The findings that autograft use predicted higher sports function and activity level and 
decreased graft rerupture at two years will require continued surveillance. In our study, those 
who had an autograft were 2.78 times less likely to incur an additional revision ACL 
reconstruction compared with patients with an allograft. But given the few number of events 
in this category, the power to detect a difference is low. As such, these findings should be 
approached with caution. Additionally, the impact of bone-tendon-bone versus soft tissue 
grafts while not a predictor for the current study will require additional study with longer 
follow-up.
Reoperation following revision ACL reconstruction is not an uncommon occurrence. Our 
rate of 13.5% reflects this. This has not been a common focus in previous studies.26 It does 
reflect an occurrence that should be discussed with patients preoperatively since one in eight 
may require further surgery following revision. Analyzing the predictors for reoperation 
does not lend itself to issues that are modifiable from a surgeon's standpoint and thus will 
remain a future issue despite our study.
The debate regarding the indications and outcomes of allograft versus autograft ACL 
reconstruction has existed for several years. Graft choice remains a topic of high interest for 
surgeons performing primary and revision ACL reconstructions.3,4,14 The key factors appear 
to be mode of processing of the allograft and the age and activity of the patient receiving the 
graft.3,12 We chose to standardize the source and processing of the allografts in this cohort. 
The MTF grafts were all fresh frozen with minimal (≤ 1.8 mRAD) to no irradiation. This is 
thought to represent the best case scenario for allografts. Different processing approaches by 
other allograft sources may be better, but the evidence regarding this is unavailable. An 
additional factor for revision reconstruction graft choice is when previously an autograft was 
utilized and thus that specific graft is lost for consideration for future revision 
reconstruction. A previous study analyzed graft choice propensity and determined surgeon 
choice to have the strongest impact upon graft choice (5× any other factor).6 Thus, surgeons 
can typically utilize the graft they determine to be best for their patient and this underscores 
the importance of the current study.
Previous studies when not stratified by age or activity have not identified a difference in 
graft failure rates. Kaeding et al. when utilizing age and activity as part of the analysis 
demonstrated a fourfold increase in graft failure for allograft in a primary cohort that 
included some irradiated grafts.12 In this current revision cohort autograft predicted 
improved sports function as measured by IKDC, KOOS subscales Sports and Recreation and 
QOL. Graft type did not predict MARX activity scales except in the small number of 
combined allograft/autograft patients. The clinical significance of this finding may be small 
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since few patients undergo a revision utilizing this graft combination. A previous analysis of 
IKDC and KOOS at six years in a primary prospective cohort demonstrated that the use of 
allograft was a significant predictor of lower IKDC and KOOS Sports and Recreation and 
QOL subscales.21
IKDC scores in the MARS revision cohort demonstrated similar levels seen in previous 
primary settings. Spindler et al. reported two and six year primary ACL reconstruction 
median IKDC scores of 75 and 77, respectively, which were similar to our score of 77 at two 
years.21 Wright et al. in a systematic review of ACL revision reconstructions with minimum 
two year follow-up reported a pooled IKDC in 202 patients of 74.8.26 However, unlike the 
IKDC the KOOS scores in the MARS revision cohort were noted to be clinically 
significantly lower. Two year median KOOS Sports and recreation was 75 compared to 85 
and 90 at two and six years for primary ACL reconstructions reported by Spindler et al.21 
KOOS QOL was 56 for the MARS cohort versus 75 and 81 (2 and 6 years) in the Spindler et 
al primary cohort.21 The MCID is 8-10 points for the KOOS.17
The Marx activity scores demonstrated dramatic decreases over the two years following 
revision ACL reconstruction. This occurred in a cohort that is older than the typical primary 
ACL reconstruction cohort and should have already had a natural decline in activity that we 
have noted every 2 years in a primary series.21,22 The typical activity progression is a 
decrease from high activity high school sports athlete, to a college intramural/recreational 
athlete, to full time employment and family obligations. At a median age of 26 year old in 
this study, most of these patients have already gone through many of these lifestyle changes 
that would decrease their activity naturally. This drop in activity at two year follow-up more 
closely resembles previous primary ACL reconstruction cohort activity levels noted at six 
year follow-up rather than 2 year follow-up.21 It is unclear whether the reduction in activity 
level is because they cannot be active due to the condition of their knee or they have chosen 
to decrease their activity to decrease the risk of future injury.
The baseline MARX scores acted as a very strong predictor for our 2 year patient reported 
measures. It predicted 2 year IKDC and four of five KOOS subscales (symptoms excepted) 
and may be a simple tool to help counsel patients (i.e. if you weren't previously active with 
your knee in the year prior to revision there is a strong chance you will not be active nor 
highly satisfied with your knee at two years). Another common predictor was time since last 
reconstruction. It appears that patients that had several years since their last reconstruction 
did well following revision. While it cannot be known why this occurs it is possible that 
patients that coped and functioned for several years previously are more likely to do well 
again.
Our study has many strengths and a few limitations. This is the largest prospective 
longitudinal cohort to ever analyze the outcomes of revision ACL reconstructions. The 
50/50 mix of academic and private practice surgeons makes the results generalizable to the 
sports medicine fellowship trained community. The use of validated patient reported 
outcome measures allows us to compare this to future and previous studies that have utilized 
these measures in other settings. The large number of patients enrolled allows us to perform 
sophisticated statistical analyses controlling for a large number of variables in order to 
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understand the predictors of inferior outcomes noted in revision ACL reconstructions. Our 
cohort study design resulted in an even split of autograft and allograft patients with high 
numbers to allow analysis to control for multiple variables without the need for 
randomization of graft choice, which would have added significant challenges in conducting 
the study. Our study design is limited in that it currently precludes on-site followup and is 
limited to two year follow-up. For this reason we may have underestimated the incidence of 
revision ACL graft rupture. Previous studies have demonstrated higher failure rates at 
minimum two year follow-up.26 This decreased rate may reflect improved results since 
many of the previous studies were more than ten years old or may reflect a lack of rupture 
detection in our study design. Future follow-up will address this with on-site clinical 
assessments.
Conclusions
Optimal graft choice for revision reconstruction was not known prior to this study. Improved 
sports function and patient reported outcome measures were obtained when an autograft was 
utilized. Additionally, use of an autograft showed a decreased risk in graft re-rupture at two 
years follow-up.
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What is known about this subject
Previous studies have demonstrated that revision ACL reconstruction outcomes are worse 
than primary ACL reconstructions. Most previous research has been Level 4 studies and 
the reason for worse outcomes has not been well elucidated.
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What this study adds to existing knowledge
This prospective multi-center cohort at two year follow-up demonstrates that the use of 
autograft for revision reconstruction results in improved patient reported outcomes as 
determined by KOOS subscales Sports and Recreation and Quality of Life and the IKDC. 
The use of an autograft for revision reconstruction resulted in patients 2.78 times less 
likely to sustain a graft rerupture within 2 years.
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Figure 1. Patient Enrollment Flow Diagram
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Table 1






Baseline Outcome Score IKDC, KOOS (5 subscales), WOMAC (3 subscales), or Marx 1 continuous
Patient Demographics
Age (years) 1 continuous
Gender 1 male, female
BMI 1 continuous
Smoking status 2 never, quit, current
Education level (years) 1 continuous (range from 1 - 16)
Baseline activity level (Marx) 1 continuous
Previous Surgical Information
Revision number 2 1, 2, 3 or more
Time since last ACLR (yrs) 1 continuous
Previous ACLR on contralateral knee 1 no, yes
Previous meniscal surgery type
 * medial 3
no, yes - repair healed/stable, yes - 
repair not healed/unstable, yes - 
excision
 * lateral 3
no, yes - repair healed/stable, yes - 
repair not healed/unstable, yes - 
excision
# of previous articular cartilage surgeries 1 no, yes
Surgeon's opinion of failure 4 traumatic, technical, biologic, other, combination
Surgeon's revision his/her own failure 1 no, yes
Cause of technical failure 4
femoral tunnel malposition, tibial 
tunnel malposition, femoral+tibial 
malposition, other, none
Prior graft type 3 autograft, allograft, both autograft + allograft, unknown
Prior graft source 3 BTB, soft tissue, BTB+soft tissue, other/unknown
Current Surgical Technique and 
Findings
Mechanism of injury 3
non-traumatic gradual onset, non-
traumatic sudden onset, traumatic 
non-contact, traumatic contact
CURRENT GRAFT TYPE 2 autograft, allograft, both
CURRENT GRAFT SOURCE 2 BTB, soft tissue, other
Interaction of (current graft type) × 
(current graft source) 4 2 × 2
Current Surgical Exposure/Technique 3
1 incision (trans-tibial), 1 incision 
(AM portal), 2 incision, arthrotomy/
other
Current Femoral Tunnel Aperture Position 5
optimum position, same tunnel - but 
compromised position, blended new 
tunnel, entirely new tunnel, added a 
2nd tunnel, OTT



















Current Tibial Tunnel Aperture Position 4
optimum position, same tunnel - but 
compromised position, blended new 
tunnel, entirely new tunnel, added a 
2nd tunnel
Current Femoral Fixation 4 interference screw, suture+button/endo, cross pin, other, combination
Current Tibial Fixation 4
interference screw, intrafix, suture
+button/endo or post, other, 
combination
Biologic Enhancement 1 no, yes
Meniscal pathology
 * medial 4 normal, no treatment for tear, repair, excision, other
 * lateral 4 normal, no treatment for tear, repair, excision, other
Articular cartilage pathology
 * medial femoral condyle (MFC) 3 normal/grade 1, grade 2, grade 3, grade 4
 * lateral femoral condyle (LFC) 3 normal/grade 1, grade 2, grade 3, grade 4
 * medial tibial plateau (MTP) 2 normal/grade 1, grade 2, grades 3/4
 * lateral tibial plateau (LTP) 2 normal/grade 1, grade 2, grades 3/4
 * patella 2 normal/grade 1, grade 2, grades 3/4
 * trochlea 2 normal/grade 1, grade 2, grades 3/4
Surgeon years of experience 1 continuous
Total # of Degrees of Freedom: 88
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Table 2




 • Males 697 (58%)


















 • Never 923 (77%)
 • Quit 154 (13%)
 • Current 109 (9%)
Previous Surgical Information





 • 1 1055 (88%)
 • 2 125 (10%)
 • 3 or more 25 (2%)
Previous ACLR on contralateral knee
 • No 1083 (90%)
 • Yes 122 (10%)
Previous Medial Meniscus Surgery
 • No 743 (62%)
 • Yes, repair healed/stable 31 (3%)
 • Yes, repair not healed/unstable 68 (6%)
 • Yes, excision 362 (30%)
Previous Lateral Meniscus Surgery
 • No 958 (80%)
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N (%)
 • Yes, repair healed/stable 28 (2%)
 • Yes, repair not healed/unstable 23 (2%)
 • Yes, excision 195 (16%)
Previous articular cartilage surgeries
 • No 1059 (88%)
 • Yes 146 (12%)
Surgeon's opinion of failure
 • Traumatic 405 (34%)
 • Technical 265 (22%)
 • Biologic 108 (9%)
 • Other 27 (2%)
 • Combination 398 (33%)
Surgeon's revision his/her own failure
 • No 859 (71%)
 • Yes 341 (28%)
Prior Graft Type
 • Autograft 816 (68%)
 • Allograft 348 (29%)
 • Both autograft + allograft 29 (2%)
 • Other/unknown 12 (<1%)
Prior Graft Source
 • BTB 639 (53%)
 • Soft Tissue 459 (38%)
 • BTB + Soft Tissue 14 (1%)
 • Other/unknown 93 (8%)
Current Surgical Information





 • Non-traumatic; gradual 339 (28%)
 • Non-traumatic; sudden onset 84 (7%)
 • Traumatic; non-contact 636 (53%)







1 two soft tissue combinations
583 (48%)
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8 Two soft tissue combinations
2 BTB + soft tissue
2 other
590 (49%)
 • Both autograft + allograft
3 Hamstring (ST)
2 Hamstring (ST) + Hamstring (ST+G)
3 Hamstring (ST) + Tibialis anterior/posterior
1 Hamstring (ST) + quad bone
3 Hamstring (ST+G)
8 Hamstring (ST+G) + tibialis anterior/posterior
7 Hamstring (ST+G) + other
1 tibialis anterior
4 2nd time revisions with serial single grafts used
32 (3%)
Current Graft Source
 • BTB 625 (52%)
 • Soft Tissue 566 (47%)
 • Both BTB + soft tissue / Other 14 (<1%)
Note: a b c represents the lower quartile a, the median b, and the upper quartile c for continuous variables.
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Table 3
Median (25%, 75% quartile) Outcome Scores over Time
Scale Baseline - T0 2 Year
IKDC 0-100 52 (38,63) 77 (61,86)*
KOOS
 • Symptoms 0-100 68 (54,82) 79 (64,89)*
 • Pain 0-100 75 (58,86) 89 (75,94)*
 • ADL 0-100 87 (69,96) 97 (88,100)*
 • Sports/recreation 0-100 45 (25,65) 75 (55,90)*
 • Quality of Life (QOL) 0-100 31 (19,44) 56 (38,75)*
WOMAC
 • Stiffness 0-100 75 (50,88) 75 (62,100)
 • Pain 0-100 85 (70,95) 95 (80,100)*
 • ADL 0-100 87 (69,96) 97 (88,100)*
Marx Activity Level 0-16 11 (4,16) 7 (2,12)*
*
denotes a significant difference in outcome score, compared to baseline score (p<0.001)
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